Remove 2009 Remove Biosimilars Remove Compounding
article thumbnail

2020 OPDP Enforcement

Eye on FDA

Heightened Role for “Bad Ad Program” – A recent interview with the new Acting Director of OPDP revealed that a primary focus for the office this past year was in relation to the biosimilars market. It was also noted that the “ Bad Ad ” program turned 10 years old this year.

article thumbnail

Top Performing Drug – Enbrel (June Edition)

PharmaShots

In 2009, Pfizer acquired Wyeth thus seeking the rights to Enbrel. Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Enbrel biosimilars Gabionline.net Centerforbiosimilars.com 7.

article thumbnail

A history of Pfizer

pharmaphorum

It was at this time they set their site at Sandwich in the UK, initially just to finish processing compounds imported from America, but due to tariffs on imported products the company rapidly expanded the plant to accommodate producing medicines from scratch. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.